Journal
FRONTIERS IN PHARMACOLOGY
Volume 11, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2020.574533
Keywords
fecal microbiota transplantation; inflammatory bowel disease; ulcerative colitis; Crohn's disease; microbiome
Categories
Funding
- National Natural Science Foundation of China [81770545, 81701746]
- MDT Project of Clinical Research Innovation Foundation, Renji Hospital, School of Medicine, Shanghai Jiaotong University [PYI-17-003]
- North Shanghai Medical Star Talent Training Program of Baoshan Branch Renji Hospital [rbxxrc-2019-008]
Ask authors/readers for more resources
Fecal microbiota transplantation (FMT) has successfully been applied for the treatment of recurrentClostridioides difficileinfection (CDI), which has led to studies on its application to other gastrointestinal diseases and extraintestinal diseases associated with gut microbiota dysbiosis. Recently, the results of FMT for patients with inflammatory bowel disease (IBD) have been encouraging. However, studies have not fully clarified the clinical application of this emerging therapy. Here, we aimed to review the current knowledge in this fast-growing field and characterize the effectiveness, safety and mechanisms of FMT for the treatment of IBD patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available